BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 8933045)

  • 1. Rocky Flats Beryllium Health Surveillance.
    Stange AW; Furman FJ; Hilmas DE
    Environ Health Perspect; 1996 Oct; 104 Suppl 5(Suppl 5):981-6. PubMed ID: 8933045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Significance of the blood beryllium lymphocyte proliferation test.
    Newman LS
    Environ Health Perspect; 1996 Oct; 104 Suppl 5(Suppl 5):953-6. PubMed ID: 8933041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible health risks from low level exposure to beryllium.
    Stange AW; Hilmas DE; Furman FJ
    Toxicology; 1996 Jul; 111(1-3):213-24. PubMed ID: 8711738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in identifying beryllium sensitization and disease.
    Middleton D; Kowalski P
    Int J Environ Res Public Health; 2010 Jan; 7(1):115-24. PubMed ID: 20195436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Process-related risk of beryllium sensitization and disease in a copper-beryllium alloy facility.
    Schuler CR; Kent MS; Deubner DC; Berakis MT; McCawley M; Henneberger PK; Rossman MD; Kreiss K
    Am J Ind Med; 2005 Mar; 47(3):195-205. PubMed ID: 15712254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Cluster of Beryllium Sensitization Traced to the Presence of Beryllium in Concrete Dust.
    Frye BC; Quartucci C; Rakete S; Grubanovic A; Höhne K; Mangold F; Gieré R; Müller-Quernheim J; Zissel G
    Chest; 2021 Mar; 159(3):1084-1093. PubMed ID: 32926872
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of in vivo and in vitro measures of beryllium sensitization.
    Bobka CA; Stewart LA; Engelken GJ; Golitz LE; Newman LS
    J Occup Environ Med; 1997 Jun; 39(6):540-7. PubMed ID: 9211212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The beryllium lymphocyte proliferation test: Relevant issues in beryllium health surveillance.
    Stange AW; Furman FJ; Hilmas DE
    Am J Ind Med; 2004 Nov; 46(5):453-62. PubMed ID: 15490468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sarcoidosis and chronic beryllium disease: similarities and differences.
    Mayer AS; Hamzeh N; Maier LA
    Semin Respir Crit Care Med; 2014 Jun; 35(3):316-29. PubMed ID: 25007084
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beryllium sensitization and chronic beryllium disease at a former nuclear weapons facility.
    Stange AW; Hilmas DE; Furman FJ; Gatliffe TR
    Appl Occup Environ Hyg; 2001 Mar; 16(3):405-17. PubMed ID: 11297055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Beryllium-stimulated neopterin as a diagnostic adjunct in chronic beryllium disease.
    Maier LA; Kittle LA; Mroz MM; Newman LS
    Am J Ind Med; 2003 Jun; 43(6):592-601. PubMed ID: 12768609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An official American Thoracic Society statement: diagnosis and management of beryllium sensitivity and chronic beryllium disease.
    Balmes JR; Abraham JL; Dweik RA; Fireman E; Fontenot AP; Maier LA; Muller-Quernheim J; Ostiguy G; Pepper LD; Saltini C; Schuler CR; Takaro TK; Wambach PF;
    Am J Respir Crit Care Med; 2014 Nov; 190(10):e34-59. PubMed ID: 25398119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interpreting borderline BeLPT results.
    Middleton DC; Mayer AS; Lewin MD; Mroz MM; Maier LA
    Am J Ind Med; 2011 Mar; 54(3):205-9. PubMed ID: 20957676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic beryllium disease among dental technicians in Israel.
    Fireman E; Kramer MR; Priel I; Lerman Y
    Sarcoidosis Vasc Diffuse Lung Dis; 2006 Oct; 23(3):215-21. PubMed ID: 18038921
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of serial medical surveillance for chronic beryllium disease in a beryllium machining plant.
    Newman LS; Mroz MM; Maier LA; Daniloff EM; Balkissoon R
    J Occup Environ Med; 2001 Mar; 43(3):231-7. PubMed ID: 11285871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Beryllium disease among construction trade workers at Department of Energy nuclear sites: A follow-up.
    Cloeren M; Dement J; Gaitens J; Hines S; Diaz L; Tembunde Y; Cranford K; Shorter J; Mosier T; Ringen K;
    Am J Ind Med; 2022 Sep; 65(9):708-720. PubMed ID: 35833586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and laboratory factors contributing to uninterpretable beryllium lymphocyte proliferation tests (BeLPT).
    Smith DE; Golden AP; Stange AW; Barker E; Mroz M; Barón AE; Ghosh D; Maier L; Cragle D; Newman LS
    Am J Ind Med; 2018 Jul; 61(7):592-604. PubMed ID: 29574954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Beryllium disease among construction trade workers at Department of Energy nuclear sites.
    Welch LS; Ringen K; Dement J; Bingham E; Quinn P; Shorter J; Fisher M
    Am J Ind Med; 2013 Oct; 56(10):1125-36. PubMed ID: 23794247
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beryllium health effects in the era of the beryllium lymphocyte proliferation test.
    Maier LA
    Appl Occup Environ Hyg; 2001 May; 16(5):514-20. PubMed ID: 11370931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Systematic review: Progression of beryllium sensitization to chronic beryllium disease.
    Seidler A; Euler U; Müller-Quernheim J; Gaede KI; Latza U; Groneberg D; Letzel S
    Occup Med (Lond); 2012 Oct; 62(7):506-13. PubMed ID: 22705916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.